Factors Associated with Time to Progression and Overall Survival in Patients with De Novo Metastatic Breast Cancer: A Colombian Cohort.

Autor:	Díaz-Casas, Sandra Esperanza, Briceño-Morales, Ximena, Puerto-Horta, Leidy Juliana, Lehmann-Mosquera, Carlos, Orozco-Ospino, Martha Cecilia, Guzmán-AbiSaab, Luis Hernán, Ángel-Aristizábal, Javier, García-Mora, Mauricio, Duarte-Torres, Carlos Alfonso, Mariño-Lozano, Iván Fernando, Briceño-Morales, Clara, Sánchez-Pedraza, Ricardo
Předmět:	BREAST cancer prognosis DISEASE progression SPECIALTY hospitals SCIENTIFIC observation CONFIDENCE intervals MIDDLE-income countries METASTASIS RETROSPECTIVE studies RISK assessment CANCER treatment TUMOR classification KAPLAN-Meier estimator DESCRIPTIVE statistics LOW-income countries TUMOR markers OVERALL survival LONGITUDINAL method
Zdroj:	Oncologist; Feb2022, Vol. 27 Issue 2, pe142-e150, 9p, 1 Diagram, 5 Charts, 1 Graph
Abstrakt:	Purpose About 10% of breast cancer (BC) is diagnosed in stage IV. This study sought to identify factors associated with time to progression (TTP) and overall survival (OS) in a cohort of patients diagnosed with de novo metastatic breast cancer (MBC), from a single cancer center in Colombia, given that information on this aspect is limited. Methodology An observational, analytical, and retrospective cohort study was carried out. Time to progression and OS rates were estimated using the Kaplan–Meier survival functions. Cox models were developed to assess association between time to progression and time to death, using a group of fixed variables. Results Overall, 175 patients were included in the study; 33.7% of patients had luminal B HER2-negative tumors, 49.7% had bone involvement, and 83.4% had multiple metastatic sites. Tumor biology and primary tumor surgery were the variables associated with TTP and OS. Patients with luminal A tumors had the lowest progression and mortality rates (10 per 100 patients/year (95% CI: 5.0-20.0) and 12.6 per 100 patients/year (95% CI: 6.9-22.7), respectively), and patients with triple-negative tumors had the highest progression and mortality rates (40 per 100 patients/year (95% CI: 23.2-68.8) and 44.1 per 100 patients/year (95% CI: 28.1-69.1), respectively). Across the cohort, the median TTP was 2.1 years (95% CI: 1.6; the upper limit cannot be reached) and the median OS was 2.4 years (95% CI: 2-4.3). Conclusions In this cohort, patients with luminal A tumors and those who underwent tumor surgery given that they presented clinical benefit (CB) after initial systemic treatment, had the lowest progression and mortality rates. Overall, OS was inferior to other series due to high tumor burden and difficulties in accessing and continuing oncological treatments. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu